GUFIC BIOSCIENCES
|
GUFIC BIOSCIENCES Last 5 Year Financial Ratios History
[Standalone]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 8.59 | 8.22 | 9.89 | 4.56 | 2.34 |
| CEPS(Rs) | 10.29 | 10.52 | 11.84 | 6.24 | 3.77 |
| DPS(Rs) | 0.10 | 0.10 | 0.10 | 0.10 | 0.05 |
| Book NAV/Share(Rs) | 53.11 | 35.88 | 27.76 | 17.89 | 13.34 |
| Tax Rate(%) | 25.53 | 25.31 | 24.44 | 23.36 | 24.69 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 15.52 | 16.81 | 17.45 | 16.18 | 13.31 |
| EBIT Margin(%) | 13.94 | 14.35 | 15.59 | 13.75 | 11.25 |
| Pre Tax Margin(%) | 12.30 | 13.33 | 14.96 | 11.13 | 7.70 |
| PAT Margin (%) | 9.16 | 9.95 | 11.30 | 8.53 | 5.80 |
| Cash Profit Margin (%) | 10.97 | 12.74 | 13.53 | 11.67 | 9.34 |
| Performance Ratios | |||||
| ROA(%) | 8.82 | 11.54 | 20.37 | 10.71 | 6.33 |
| ROE(%) | 19.57 | 25.84 | 43.31 | 29.22 | 22.17 |
| ROCE(%) | 17.37 | 23.23 | 47.29 | 30.05 | 21.01 |
| Asset Turnover(x) | 0.96 | 1.16 | 1.80 | 1.26 | 1.09 |
| Sales/Fixed Asset(x) | 3.82 | 3.76 | 5.17 | 3.94 | 5.14 |
| Working Capital/Sales(x) | 4.12 | 4.55 | 6.31 | 5.35 | 11.67 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.26 | 0.27 | 0.19 | 0.25 | 0.19 |
| Receivable days | 103.93 | 81.36 | 59.40 | 81.43 | 97.98 |
| Inventory Days | 74.53 | 68.14 | 45.18 | 76.30 | 101.05 |
| Payable days | 159.61 | 167.52 | 124.89 | 184.25 | 227.30 |
| Valuation Parameters | |||||
| PER(x) | 32.96 | 22.70 | 25.18 | 25.05 | 20.15 |
| PCE(x) | 27.53 | 17.74 | 21.02 | 18.30 | 12.51 |
| Price/Book(x) | 5.33 | 5.20 | 8.97 | 6.39 | 3.53 |
| Yield(%) | 0.04 | 0.05 | 0.04 | 0.09 | 0.11 |
| EV/Net Sales(x) | 3.90 | 3.00 | 3.14 | 2.36 | 1.47 |
| EV/Core EBITDA(x) | 21.23 | 15.12 | 16.20 | 13.12 | 9.63 |
| EV/EBIT(x) | 23.99 | 18.05 | 18.51 | 16.12 | 12.66 |
| EV/CE(x) | 3.70 | 3.15 | 7.41 | 5.03 | 2.27 |
| M Cap / Sales | 3.52 | 2.62 | 3.10 | 2.27 | 1.21 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 16.80 | -11.36 | 59.76 | 28.74 | 8.00 |
| Core EBITDA Growth(%) | 7.89 | -9.20 | 72.42 | 51.37 | 15.45 |
| EBIT Growth(%) | 14.00 | -13.06 | 85.30 | 62.00 | -3.23 |
| PAT Growth(%) | 8.07 | -16.84 | 116.68 | 94.96 | 3.41 |
| EPS Growth(%) | 4.48 | -16.84 | 116.67 | 94.96 | -16.98 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.60 | 0.90 | 0.23 | 0.32 | 0.90 |
| Current Ratio(x) | 1.61 | 1.61 | 1.72 | 1.51 | 1.14 |
| Quick Ratio(x) | 1.08 | 0.97 | 1.10 | 1.01 | 0.63 |
| Interest Cover(x) | 8.53 | 13.98 | 24.64 | 5.23 | 3.17 |
| Total Debt/Mcap(x) | 0.11 | 0.17 | 0.03 | 0.06 | 0.32 |
Compare Financial Ratios of peers of GUFIC BIOSCIENCES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GUFIC BIOSCIENCES | ₹4,043.6 Cr | -9.7% | -7.2% | 37.4% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹431,352.0 Cr | 1.7% | -4.7% | 48.8% | Stock Analytics | |
| DIVIS LABORATORIES | ₹159,265.0 Cr | 4.4% | 3.1% | 66% | Stock Analytics | |
| CIPLA | ₹120,035.0 Cr | -0.9% | -1.7% | 17.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹101,286.0 Cr | -1% | -8.9% | 6.5% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹95,461.4 Cr | -1% | -4% | 48.4% | Stock Analytics | |
GUFIC BIOSCIENCES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GUFIC BIOSCIENCES | -9.7% |
-7.2% |
37.4% |
| SENSEX | 1.8% |
-2.5% |
19.9% |
You may also like the below Video Courses
